Related references
Note: Only part of the references are listed.Inducible de novo expression of neoantigens in tumor cells and mice
Martina Damo et al.
NATURE BIOTECHNOLOGY (2021)
Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden
Laura P. Stabile et al.
JCI INSIGHT (2021)
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution
Subramanian Venkatesan et al.
CANCER DISCOVERY (2021)
E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion
Eleonora Ottina et al.
ONCOGENE (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C
Jason G. Kettle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Capturing the primordial Kras mutation initiating urethane carcinogenesis
Siqi Li et al.
NATURE COMMUNICATIONS (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy
Amy J. Wisdom et al.
NATURE COMMUNICATIONS (2020)
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
Emily J. Lelliott et al.
SCIENTIFIC REPORTS (2019)
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Yochai Wolf et al.
CELL (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
A Rabbit Monoclonal Antibody against the Antiviral and Cancer Genomic DNA Mutating Enzyme APOBEC3B
William L. Brown et al.
ANTIBODIES (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Restoration of Endogenous Retrovirus Infectivity Impacts Mouse Cancer Models
Eleonora Ottina et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
Howard Y. Li et al.
CANCER IMMUNOLOGY RESEARCH (2017)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma
David G. McFadden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Immune responses to endogenous retroelements: taking the bad with the good
George Kassiotis et al.
NATURE REVIEWS IMMUNOLOGY (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses
Nikhil S. Joshi et al.
IMMUNITY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity
Charles Swanton et al.
CANCER DISCOVERY (2015)
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
Peter M. K. Westcott et al.
NATURE (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Elza C. de Bruin et al.
SCIENCE (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Evidence for APOBEC3B mutagenesis in multiple human cancers
Michael B. Burns et al.
NATURE GENETICS (2013)
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Steven A. Roberts et al.
NATURE GENETICS (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression
Michel DuPage et al.
CANCER CELL (2011)
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
Michel DuPage et al.
NATURE PROTOCOLS (2009)
The differential effects of mutant p53 alleles on advanced murine lung cancer
EL Jackson et al.
CANCER RESEARCH (2005)
A new mathematical model for relative quantification in real-time RT-PCR
MW Pfaffl
NUCLEIC ACIDS RESEARCH (2001)
The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors
JC Yang et al.
JOURNAL OF IMMUNOTHERAPY (2000)
Share Paper
